Clinical outcome at the age of 18 months (this study) or 6 months (Bharadwaj and Bhat [6])
| . | Normothermia, n (%) . | Hypothermia, n (%) . | Ratio (95% CI) . |
|---|---|---|---|
| This study: 18 months | |||
| Total | 84 | 78 | |
| Lost to follow-up | 5 (79 followed) | 2 (76 followed) | |
| Died | 29 (36.7%) | 22 (28.9%) | 0.79 (0.50–1.24) |
| Neurological abnormality | 17 (21.5%) | 5 (6.6%) | 0.31 (0.12–0.79) |
| Normal survivor | 33 (41.8%) | 49 (64.5%) | 1.54 (1.13–2.10) |
| Previous study [6]: 6 months | |||
| Total | 62 | 62 | |
| Lost to follow-up | 3 (59 followed) | 5 (57 followed) | |
| Died | 6 (10.2%) | 3 (5.3%) | 0.52 (0.14–1.97) |
| Neurological abnormality | 12 (20.3%) | 2 (3.5%) | 0.17 (0.04–0.74) |
| Normal survivor | 41 (69.5%) | 52 (91.2%) | 1.31 (1.09–1.58) |
| Meta-estimate | |||
| Normal survivor | 1.37 (1.17–1.61) | ||
| . | Normothermia, n (%) . | Hypothermia, n (%) . | Ratio (95% CI) . |
|---|---|---|---|
| This study: 18 months | |||
| Total | 84 | 78 | |
| Lost to follow-up | 5 (79 followed) | 2 (76 followed) | |
| Died | 29 (36.7%) | 22 (28.9%) | 0.79 (0.50–1.24) |
| Neurological abnormality | 17 (21.5%) | 5 (6.6%) | 0.31 (0.12–0.79) |
| Normal survivor | 33 (41.8%) | 49 (64.5%) | 1.54 (1.13–2.10) |
| Previous study [6]: 6 months | |||
| Total | 62 | 62 | |
| Lost to follow-up | 3 (59 followed) | 5 (57 followed) | |
| Died | 6 (10.2%) | 3 (5.3%) | 0.52 (0.14–1.97) |
| Neurological abnormality | 12 (20.3%) | 2 (3.5%) | 0.17 (0.04–0.74) |
| Normal survivor | 41 (69.5%) | 52 (91.2%) | 1.31 (1.09–1.58) |
| Meta-estimate | |||
| Normal survivor | 1.37 (1.17–1.61) | ||
CI, confidence interval.
Clinical outcome at the age of 18 months (this study) or 6 months (Bharadwaj and Bhat [6])
| . | Normothermia, n (%) . | Hypothermia, n (%) . | Ratio (95% CI) . |
|---|---|---|---|
| This study: 18 months | |||
| Total | 84 | 78 | |
| Lost to follow-up | 5 (79 followed) | 2 (76 followed) | |
| Died | 29 (36.7%) | 22 (28.9%) | 0.79 (0.50–1.24) |
| Neurological abnormality | 17 (21.5%) | 5 (6.6%) | 0.31 (0.12–0.79) |
| Normal survivor | 33 (41.8%) | 49 (64.5%) | 1.54 (1.13–2.10) |
| Previous study [6]: 6 months | |||
| Total | 62 | 62 | |
| Lost to follow-up | 3 (59 followed) | 5 (57 followed) | |
| Died | 6 (10.2%) | 3 (5.3%) | 0.52 (0.14–1.97) |
| Neurological abnormality | 12 (20.3%) | 2 (3.5%) | 0.17 (0.04–0.74) |
| Normal survivor | 41 (69.5%) | 52 (91.2%) | 1.31 (1.09–1.58) |
| Meta-estimate | |||
| Normal survivor | 1.37 (1.17–1.61) | ||
| . | Normothermia, n (%) . | Hypothermia, n (%) . | Ratio (95% CI) . |
|---|---|---|---|
| This study: 18 months | |||
| Total | 84 | 78 | |
| Lost to follow-up | 5 (79 followed) | 2 (76 followed) | |
| Died | 29 (36.7%) | 22 (28.9%) | 0.79 (0.50–1.24) |
| Neurological abnormality | 17 (21.5%) | 5 (6.6%) | 0.31 (0.12–0.79) |
| Normal survivor | 33 (41.8%) | 49 (64.5%) | 1.54 (1.13–2.10) |
| Previous study [6]: 6 months | |||
| Total | 62 | 62 | |
| Lost to follow-up | 3 (59 followed) | 5 (57 followed) | |
| Died | 6 (10.2%) | 3 (5.3%) | 0.52 (0.14–1.97) |
| Neurological abnormality | 12 (20.3%) | 2 (3.5%) | 0.17 (0.04–0.74) |
| Normal survivor | 41 (69.5%) | 52 (91.2%) | 1.31 (1.09–1.58) |
| Meta-estimate | |||
| Normal survivor | 1.37 (1.17–1.61) | ||
CI, confidence interval.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
